Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?

The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Filspari's (sparsentan) potential to earn increasing revenues for the company. The drug, approved for treating IgA nephropathy, a form of kidney disease, has been witnessing solid uptake in the market. Travere recorded sales of $40 million in first-quarter 2024, up 65% year-over-year, primarily driven by an increase in sales from the ongoing commercial launch of Filspari. The company is also looking to e ...